[ccp4bb] Research Fellow Position - Structural Biology of Host-Pathogen Interactions (Toronto, Canada)

[Jean-Philippe Julien]

Job description
Dr. Julien’s laboratory at The Hospital for Sick Children Research Institute is 
looking for a Research Fellow to join our Structural Biology team. The 
successful candidate will participate in the characterization of host-pathogen 
interactions by using a combination of in silico, biochemical, biophysical, 
structural, and protein engineering techniques. We are looking for a driven and 
enthusiastic scientist who demonstrates passion and creativity towards the 
structure-function study of important pathogenic targets and who can thrive in 
a highly-collaborative setting.

Roles & Responsibilities

  *   Optimize library designs from in silico structural principles leveraging 
latest developments in structure prediction algorithms;
  *   Design and optimize constructs for expression in E.coli and mammalian 
cells;
  *   Biophysically characterize purified constructs for their Tm, Tagg and 
polydipersity, and perform ITC and BLI binding experiments to determine binding 
thermodynamics and kinetics;
  *   Use Cryo-Electron Microscopy to determine the structure of designed 
constructs in complex with their receptors to enable iterative structure-based 
design.
Desired Skills and Experience

  *   Structural Biologist with a PhD in Biochemistry, Molecular Biology, 
Computational Biology or related field;
  *   Strong knowledge in using Cryo-Electron Microscopy to study protein 
structure, especially in a context of structure-guided design;
  *   Experience in protein engineering, molecular biology, protein expression 
in various systems, purification and biophysical characterization;
  *   Practical experience in using in silico approaches to improve binding 
interfaces is a plus;
  *   Demonstrated ability to participate in collaborative scientific projects;
  *   Organization skills, efficiency and meticulous record keeping.
How to Apply?
Send your CV and a letter of intent to 
jean-philippe.jul...@sickkids.ca 
before March 31st, 2022. Successful candidates will be notified for interviews, 
at which time two letters of reference will also be required.

About Us
Dr. Julien's laboratory (https://lab.research.sickkids.ca/julien/) focuses on 
the molecular characterization of biologics by studies of their interactions 
with cell surface receptors in therapeutic development, and with pathogens 
guiding vaccine design primarily against Plasmodium falciparum malaria, HIV-1, 
and COVID-19. Dr. Julien’s laboratory is located in the Molecular Medicine 
Program of The Peter Gilgan Centre for Research and Learning at SickKids, a 
21-story, 750,000 square-foot facility in downtown Toronto that incorporates an 
open-concept design, state-of-the-art research facilities, and collaborative 
work spaces.
As a member of the SickKids community, you will become part of a world-renowned 
organization dedicated to fulfilling a vision of Healthier Children, A Better 
World. For over 135 years, SickKids has worked hard to make the world a better 
place for children and their families. Each day, people around the organization 
are doing meaningful work that directly, and often indirectly, benefits 
children in Canada and around the world.




This e-mail may contain confidential, personal and/or health 
information(information which may be subject to legal restrictions on use, 
retention and/or disclosure) for the sole use of the intended recipient. Any 
review or distribution by anyone other than the person for whom it was 
originally intended is strictly prohibited. If you have received this e-mail in 
error, please contact the sender and delete all copies.



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

[ccp4bb] PhD student position - drug discovery & ADP-ribosylation

[Lari Lehtiö]

Dear colleagues,

There is a doctoral researcher position available in my team on drug discovery 
in the field of ADP-ribosylation. We use extensively crystallography to support 
inhibitor development efforts. Please forward this in case you know someone who 
may be interested.

https://rekry.saima.fi/certiahome/open_job_view.html?did=5600&lang=en&id=13109&jc=1

Best wishes,

Lari

__
Lari Lehtiö, Professor
Faculty of Biochemistry and Molecular Medicine
P.O.Box 5400
FIN-90014 University of Oulu
Finland
https://www.oulu.fi/en/research-groups/structural-and-chemical-biology-adp-ribosylation
https://twitter.com/LabLehtio
_



To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/

[ccp4bb] CCPBioSim Industry Talk

[Sarah Fegan - STFC UKRI]

Dear Colleagues,

The next event in the Industry Talk Series will take place online 13 April 2022 
at 3pm (British Summer Time). The title is "Adopting a collaborative mindset in 
industrial drug discovery in the AI era" and the speakers are Ewa Chudyk and 
Meir Glick from Vertex Pharmaceuticals, see abstract below.

The registration deadline is 11 April 2022. The registration link and all 
details can be found at https://www.ccpbiosim.ac.uk/collaboration22.

Best wishes,
Sarah


Abstract:

The discovery of a new drug is a complex and expensive process, involving the 
collaboration of many interdisciplinary teams of scientists. Along the way, 
computational chemists can contribute to and accelerate the decision-making 
process by assessing available data with relevant analysis methods. At various 
stages of the process, this usually involves partnering with medicinal 
chemists, DMPK scientists, biologists, toxicologists, and formulation 
scientists, amongst others. Applying “predict first” solutions involves 
reaching for both traditional computational chemistry tools as well as novel 
AI-based methods when working as part of these interdisciplinary teams to 
identify opportunities of the highest potential impact on the project. 
Appropriate models are then applied for given hypotheses and assessed after 
experiments are performed.

In this talk, we will give a general overview of the Vertex Pharmaceuticals 
drug discovery approach. We will also provide a computational chemist’s 
perspective based on our own experience in the industry. This will include 
diverse examples of computational methods used depending on the project’s 
needs. These consist of mining large datasets, building machine learning-based 
predictive models, docking virtual compound databases, including quantum 
chemistry calculations in chemical synthesis planning, running molecular 
simulations of large protein complexes, or using deep learning models for cell 
segmentation image recognition, amongst others. We will also share practical 
considerations of working in the industry, such as project timescales or 
partnering with interdisciplinary experimental teams. Finally, we will discuss 
the impact of collaboration, both within the industry and with academia to seek 
innovative solutions to complex problems.


This email and any attachments are intended solely for the use of the named 
recipients. If you are not the intended recipient you must not use, disclose, 
copy or distribute this email or any of its attachments and should notify the 
sender immediately and delete this email from your system. UK Research and 
Innovation (UKRI) has taken every reasonable precaution to minimise risk of 
this email or any attachments containing viruses or malware but the recipient 
should carry out its own virus and malware checks before opening the 
attachments. UKRI does not accept any liability for any losses or damages which 
the recipient may sustain due to presence of any viruses.




To unsubscribe from the CCP4BB list, click the following link:
https://www.jiscmail.ac.uk/cgi-bin/WA-JISC.exe?SUBED1=CCP4BB&A=1

This message was issued to members of www.jiscmail.ac.uk/CCP4BB, a mailing list 
hosted by www.jiscmail.ac.uk, terms & conditions are available at 
https://www.jiscmail.ac.uk/policyandsecurity/